Rafarma Pharmaceuticals, Inc. (RAFA)
- Previous Close
0.1020 - Open
0.1105 - Bid --
- Ask --
- Day's Range
0.1105 - 0.1105 - 52 Week Range
0.1000 - 0.4270 - Volume
500 - Avg. Volume
26,477 - Market Cap (intraday)
110.285M - Beta (5Y Monthly) -0.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0140 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
rafarma.si--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: RAFA
Performance Overview: RAFA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RAFA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RAFA
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-87.92%
Return on Assets (ttm)
-0.04%
Return on Equity (ttm)
-0.07%
Revenue (ttm)
133.33k
Net Income Avi to Common (ttm)
-117.22k
Diluted EPS (ttm)
-0.0140
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: RAFA
RAFA does not have Company Insights